價格 | 詢價 |
包裝 | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 其他 |
更新日期 | 2022-10-22 |
中文名稱:AP1903 | 英文名稱:AP1903 |
CAS:195514-63-7 | 純度規(guī)格: >98% HPLC |
CAS | 195514-63-7 |
中文名稱 | AP1903 |
英文名稱 | AP1903 |
MW | 1411.63 |
MF | C78H98N4O20 |
沸點 | 1307.5±65.0 °C(Predicted) |
密度 | 1?+-.0.06 g/cm3(Predicted) |
酸度系數(shù)(pKa) | 13.70±0.46(Predicted) |
體內(nèi)研究 | Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum human GH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg.
|
體外研究 | The human fibrosarcoma line HT1080 is engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human first apoptosis signal (Fas) intracellular domain. Rimiducid (AP1903) elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC 50 of ≈0.1 nM. Maximal killing occurred in the presence of 3 to 10 nM Rimiducid (AP1903), and the IC 50 is approximately 0.2 nM. LV′VFas-transduced T lymphocytes expressing high levels of CD25 (top panel) are eliminated by with 66%±7.5% (n=10) efficiency. When cells are examined after CD25 expression returned to basal levels, 63%±4.7% (n=9) killing is observed after Rimiducid treatment.
|
成立日期 | 注冊資本 | ||
員工人數(shù) | 年營業(yè)額 | ||
主營行業(yè) | 中間體,化學(xué)試劑,醫(yī)藥原料 | 經(jīng)營模式 | 試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
上海嘉定區(qū)澄瀏公路52號
|
2024-12-25 | |
詢價 |
上海煊翎生物科技有限公司
|
2024-12-25 | ||
¥568 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 | |
¥2099.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
詢價 |
VIP8年
|
江蘇艾康生物醫(yī)藥研發(fā)有限公司
|
2022-10-22 | |
¥5000 |
廣州市齊云生物技術(shù)有限公司
|
2022-10-22 | ||
¥2100 |
青島梁會計
|
2022-10-22 | ||
詢價 |
上海禾午生物科技有限公司
|
2020-11-03 | ||
¥3320 |
上海偉寰生物科技有限公司
|
2020-01-17 |